These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30099379)

  • 21. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
    Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinal metabolic and structural alterations in response to aflibercept treatment in neovascular age-related macular degeneration.
    Jakobsen DB; Torp TL; Stefansson E; Peto T; Grauslund J
    Acta Ophthalmol; 2019 Aug; 97(5):525-531. PubMed ID: 30549221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
    Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
    Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
    Sawada T; Wang X; Sawada O; Saishin Y; Ohji M
    Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR THE TREATMENT OF A PATIENT WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION.
    Andrade GC; Dias JRO; Maia A; Farah ME; Mitne S; Rodrigues EB
    Retin Cases Brief Rep; 2018 Spring; 12(2):93-96. PubMed ID: 29554051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact.
    Singh SR; Dogra A; Stewart M; Das T; Chhablani J
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):561-568. PubMed ID: 28971631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Visual and anatomical outcomes of three intravitreal aflibercept injections in eyes with neovascular form of age-related macular degeneration].
    Kałuiny JJ; Majer A; Jaworowska-Cieślińska I
    Klin Oczna; 2015; 117(1):9-13. PubMed ID: 26349151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
    Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
    Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept.
    Sulzbacher F; Roberts P; Munk MR; Kaider A; Kroh ME; Sacu S; Schmidt-Erfurth U;
    Invest Ophthalmol Vis Sci; 2014 Dec; 56(2):1158-67. PubMed ID: 25503456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.
    Lotery A; Griner R; Ferreira A; Milnes F; Dugel P
    Eye (Lond); 2017 Dec; 31(12):1697-1706. PubMed ID: 28731052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT.
    Yogi R; Stewart M; Chhablani J
    Retin Cases Brief Rep; 2017 Spring; 11(2):111-113. PubMed ID: 27078613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
    Ogura Y; Roider J; Korobelnik JF; Holz FG; Simader C; Schmidt-Erfurth U; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Am J Ophthalmol; 2014 Nov; 158(5):1032-8. PubMed ID: 25068637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
    Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
    Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes.
    de Andrade GC; de Oliveira Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):245-250. PubMed ID: 29664981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.